Conclusion
lung cancer, lung cancer carcinogenesis
LUNG CANCER, LUNG
CyPath Lung is a non-invasive, sputum-based test for the early diagnosis of lung cancer. It uses a flow cytometric platform to analyze the cellular content of sputum with the analysis being fully automated and thus unbiased. The test is robust to differences in sample handling and processing and captures important predictive factors of early lung cancer carcinogenesis. The test performs well at 82% sensitivity and 88% specificity and achieves comparable performance when applied to an independent set of samples collected on a different flow cytometer. The test is also accurate in early stages (I and II) and in cases with nodules < 20 mm.